Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement
Executive Summary
AstraZeneca agreed in late December to pay AtheroGenics a $50 million upfront fee and another $950 million in regulatory and commercial milestones for the biotech's VCAM-I inhibitor AGI-1067. Though many heralded the deal as a win-win for both companies, a closer analysis shows that AtheroGenics continues to shoulder the development costs--and risks--of the Phase III product.
You may also be interested in...
GSK/Actelion: Phase III Value Is in the Eye of the Beholder
GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.
GSK/Actelion: Phase III Value Is in the Eye of the Beholder
GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.
Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.